Pharmexcil appoints Bhavin Mukund Mehta as Vice Chairman
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
EBITDA margins expand to 31.3%
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The brand Magtein by Threotech has a sales value of approximately US $438 million
Subscribe To Our Newsletter & Stay Updated